Cassava Sciences Receives Notice Of Allowance For US Patent Application Titled "Alzheimer's Disease Assay In A Living Patient" For Determining Likelihood Of Alzheimer's Disease Or Mild Cognitive Impairment Due To AD
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences has received a Notice of Allowance for a US patent application titled 'Alzheimer's Disease Assay In A Living Patient,' which is designed to determine the likelihood of Alzheimer's Disease or Mild Cognitive Impairment due to AD.
May 24, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences has received a Notice of Allowance for a US patent application for an Alzheimer's Disease assay, which could significantly enhance their product portfolio and market position in AD diagnostics.
The Notice of Allowance for the patent application indicates that Cassava Sciences is likely to secure intellectual property protection for their Alzheimer's Disease assay. This development could enhance their product offerings and potentially lead to increased market share and revenue in the AD diagnostics space.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100